Johns Hopkins University-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2023

  1. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

2015

  1. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

    Clinical Cancer Research, Vol. 21, Núm. 3, pp. 553-560

  2. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor i kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

    Investigational New Drugs, Vol. 33, Núm. 2, pp. 357-370